Abstract: Previous investigators have argued that one of the two most important contributors to improved human survival is the treatment of cardiovascular disease. Among Swiss inhabitants age 65 and over, 90% of the 1994-2010 decline in the overall death rate was due to the decline in the rate of deaths from diseases of the circulatory system. Little if any of the decline in cardiovascular mortality is likely to have been due to changes in behavioral risk factors, especially tobacco use and obesity.
Introduction
During the period 1994-2010, life expectancy at birth in Switzerland increased by 4 years, from 78.7 to 82.7, and the standardized death rate per 100,000 Swiss inhabitants declined by 270, from 1146 to 876. 1 The standardized rate of deaths from diseases of the circulatory system (ICD-10 Chapter IX) declined by 202, from 510 to 308.
2 Hence, 75% (= 202/270) of the decline in the overall death rate was due to the decline in the rate of deaths from diseases of the circulatory system. 3 It is reasonable to estimate that the decline in the rate of deaths from diseases of the circulatory system increased life expectancy at birth in Switzerland by 3.0 years (= 75% × 4.0 years) during the period 1994-2010. Weisfeldt and Zieman (2007) said that "one of the two most important contributors to improved human survival is the treatment of cardiovascular disease." 4 Extensive surveys of previous research (Weisfeldt and Zieman (2007) , Ford and Capewell (2011) ) suggest that, in principle, the substantial decline in Swiss cardiovascular mortality could have been due to two main types of factors. The first type is improvements in behavioral risk factors, 5 especially tobacco use and obesity. Tobacco consumption has declined in Switzerland: smoking prevalence among permanent residents of Switzerland ages 14-65 declined from 33% in 2001 to 27% in 2010 (Swiss Association for Smoking Prevention (2014)). But apparently this has made only a minor contribution to the decline in Swiss cardiovascular mortality: according to the Federal Statistical Office (2009), during the period 1995-2007, the number of smoking-attributable deaths of people age 65 and over declined by only 388, which is only 13% of the decline from 23,807 to 20,865 in the number of deaths of people age 65 and over from diseases of the circulatory system. Moreover, during the period 1992-2007, the fraction of the adult Swiss population that was overweight (BMI 25-30) increased from 24.9% to 29.2%, and the fraction that was obese (BMI > 30) increased from 5.4% to 8.1% (Schneider, Venetz and Berardo (2009) ).
The second type of factor that previous research suggests may have caused the substantial decline in Swiss cardiovascular mortality is medical innovation: the introduction and use of new medical products and procedures. It is useful to distinguish between two types of medical innovation: pharmaceutical innovation and non-pharmaceutical medical innovation. Weisfeldt and Zieman (2007) , argued that "pharmaceutical agents play a major role in prevention of atherosclerosis and its consequences: heart attack, stroke, and heart failure"; "protein enzymes, receptors, or channels identified by the pharmaceutical industry as 'drugable targets' have led to striking, remarkable, and repeated achievement"; and that the "marked reduction in cardiovascular disease and its consequences was largely driven by the development and implementation of drugs for long-term use and by complicated and 1 Sources: Eurostat demo_mlexpec and hlth_cd_asdr tables. Life expectancy and the standardized death rate are closely (inversely) related, since both are based on age-specific death rates. 2 Cardiovascular disease was the main cause of 21,959 deaths (at all ages) in 2010. (There were 62,649 deaths in Switzerland in 2010.) Cardiovascular disease was a secondary cause of 17,712 deaths (at all ages) in 2010. (Source: Federal Statistical Office (2013) ). 3 Among Swiss inhabitants age 65 and over, 90% (= 947/1050) of the decline in the overall death rate was due to the decline in the rate of deaths from diseases of the circulatory system. 4 The other contributor was eliminating the scourge of common infectious diseases through public health measures, vaccines, and antibiotic drug development. 5 The Psychology Dictionary defines a behavioral risk factor as follows: "any particular behavior or behavior pattern which strongly yet adversely affects health. It increases the chances of developing a disease, disability, or syndrome. Examples of these factors include tobaccco use, alcohol consumption, smoking, obesity, physical activity, and sexual activity." http://psychologydictionary.org/behavioral-risk-factor/#ixzz2rnu5J68P costly procedures and operations for acute disease management. " Ford et al (2007) estimated that 47% of the decline between 1980 and 2000 in the age-adjusted U.S. death rate for coronary heart disease was due to "treatments," 24% was due to reductions in total cholesterol, and 20% was due to reductions in systolic blood pressure. Many of the treatments identified by Ford et al (2007) were pharmaceutical treatments, and pharmaceuticals (e.g. statins) probably also played an important role in reducing cholesterol and blood pressure. Also, Ford and Capewell (2011) argued that "aggressive recommendations regarding targets for cholesterol, glucose, and blood pressure evolved, and the medications available to health care providers to treat these risk factors proliferated for secondary prevention, then increasingly for primary prevention. Revascularization, coronary artery bypass surgery, and percutaneous coronary interventions emerged as evidence-based interventional approaches to chronic disease, then to [acute myocardial infarction], as well." This study will examine the impact of cardiovascular drug innovation on the longevity of elderly residents of Switzerland using cross-sectional patient-level data on about 22 thousand patients insured by a major health insurer (CSS) during the period 2003-2011. The basic theory and methodology are discussed in Section 2. Descriptive statistics are presented in Section 3. Empirical results are presented in Section 4. A summary and conclusions are provided in Section 5.
Theory and methodology

A. Basic hypothesis
Our basic hypothesis is that longevity (or time till death at a given age) is positively related to the quality of medical goods and services used. The quality of medical goods and services is not directly observable. However, we also hypothesize that, in general, the average quality of newer (later vintage) goods and services is higher than that of older (earlier vintage) goods and services. The hypotheses that vintage has a positive effect on quality, and that quality has a positive effect on longevity, imply that vintage has a positive effect on longevity.
Robert Solow (1960) introduced the concept of vintage into economic analysis. This was one of the contributions to the theory of economic growth that the Royal Swedish Academy of Sciences cited when it awarded Solow the 1987 Alfred Nobel Memorial Prize in Economic Sciences:
Solow's basic idea was that technical progress is "built into" [or embodied in] machines and other capital goods and that this must be taken into account when making empirical measurements of the role played by capital.
6 This idea then gave birth to the "vintage approach"… Solow's empirical results naturally gave the formation of capital a markedly higher status in explaining the increase in production per employee. The most important aspect of Solow's article was not so much the empirical outcome, but the method of analyzing "vintage capital". Nowadays, the vintage capital concept has many other applications and is no longer solely employed in analyses of the factors underlying economic growth… The vintage approach has proved invaluable, both from the theoretical point of view and in applications..." (Nobelprize.org (2014) ). 6 Solow assumed that technical progress is embodied in machines because machine manufacturers perform R&D. Since the medical substances and devices industry is much more research-intensive than the machinery industry (National Science Foundation (2014)), new medical treatments may embody even more technical progress than new machines.
Subsequently, Grossman and Helpman (1991) argued that "almost every product exists on a quality ladder, with variants below that may already have become obsolete and others above that have yet to be discovered," and that "each new product enjoys a limited run at the technological frontier, only to fade when still better products come along. " Harper (2007, p. 103) argued that "new improved models of high-tech equipment that embody improvements are frequently introduced and marketed alongside older models."
B. Econometric model
We will investigate the effect of the vintage of the cardiovascular drugs used by an individual on his or her longevity (time till death), controlling for several demographic characteristics and indicators of health status. We will do this by estimating models of the following general form: We are able to track a patient's vital status until 12/31/2011: 8 years after the end of the period in which cardiovascular drug use (and other variables) are measured. If individual i did not die by December 31, 2011, his or her death date is unknown -we only know that the death date was or will be after December 31, 2011. Hence, the variable time_till_death is right-censored. We will estimate versions of eq. (1) using a statistical procedure (the SAS LIFEREG procedure) that fits parametric models to failure time data that can be uncensored, right censored, left censored, or interval censored. We will assume that the number of years from 12/31/2003 until the date of death has the Weibull distribution, one of the most commonly used distributions in failure time analysis. The probability density function of a Weibull random variable x is:
As discussed below, this variable is right-censored. Our estimation procedure will account for this.
where k > 0 is the shape parameter and λ > 0 is the scale parameter of the distribution.
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The mean of a Weibull random variable can be expressed as λ (1+(1/k)) where (z) is the Gamma function:
We assume that the scale parameter λ depends on patient characteristics X as follows: λ = exp( X). Hence ln  =  X, and ln(mean survival time) =  X + ln((1+(1/k))). Therefore the estimated coefficient on a patient characteristic X1 indicates the percentage change in mean survival time attributable to a unit increase in X1. Our estimation procedure allows us to use right-censored survival data, but the precision of our estimates will be greater, the larger the fraction of the observations that are not censored. To increase the precision of the estimates, we will analyze people who were 65 years and older ("the elderly") on 1 January 2003. The survival times of 36% of these people are not censored.
C. Measurement of drug vintage
CSS provided data on all outpatient prescription drugs used by each individual during 2003. 10 In the CSS data, prescriptions are identified by the World Health Organization (WHO)'s Anatomical Therapeutic Chemical (ATC) classification system, which WHO says is "the gold standard for international drug utilization research" (WHO Collaborating Centre for Drug Statistics Methodology (2014)). In the WHO ATC system, active substances (drugs) are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties. Drugs are classified in groups at five different levels. The drugs are divided into fourteen main groups (1st level), with pharmacological/therapeutic subgroups (2nd level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. The 2nd, 3rd and 4th levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups. This is illustrated by Table 1 If newer drugs tend to be therapeutically superior to older drugs within the same class, and newer classes of drugs tend to be superior to older classes of drugs, the estimates of  and  should both be positive and significant. (2) is partly due to the fact that using newer cardiovascular drugs contributes to better health, which in turn leads to less utilization of medical care, 14 controlling for the quantity of medical care used will result in underestimation of the effect of cardiovascular drug innovation on longevity.
Ideally, we would like to control for other potential determinants of longevity in eq. (1), such as measures of socioeconomic status (e.g. income and education) and use of nonpharmaceutical medical innovations.However, previous studies have shown that controlling for measures of socioeconomic status does not reduce estimates of the effect of pharmaceutical innovation on longevity. In his analysis of longitudinal country-level data on 30 developing and high-income countries, Lichtenberg (2013a) found that controlling for income, education and other factors did not reduce (and in some cases even increased) the effect of drug vintage on longevity. In his analysis of patient-level data on elderly Americans, Lichtenberg (2012) found that controlling for an extensive set of attributes (the mean year the person started taking his or her medications, which may serve as a proxy for mean duration of medical conditions; race; education; family income as a percent of the poverty line; insurance coverage; Census region; marital status; and over 100 medical condition dummy variables) had virtually no effect on estimates of the effect of drug vintage on longevity.
The apparent insensitivity of estimates of the effect of pharmaceutical innovation on longevity to controlling for socioeconomic factors may be due to the fact that heterogeneous pharmaceutical treatment of patients is primarily due to physician practice variation. Wennberg (2004) argues that "unwarranted [treatment] variation-variation not explained by illness, patient preference, or the dictates of evidence-based medicine-is a ubiquitous feature of U.S. health care." A large number of studies have documented the importance of unexplained variation in medical care in general and prescribing behavior in particular. Wennberg and Wennberg (2000) examined variation in nine drugs or classes of drugs among members of Blue Cross and Blue Shield of Michigan, and argued that "evidence does not, per se, ensure that pharmaceuticals are always used rationally." Lee et al (2008) showed that "pediatric and adult transplant physicians differed significantly in their management strategies for chronic myeloid leukemia, acute and chronic graft-versus-host disease, and choice of graft source for patients with aplastic anemia. Among adult transplant physicians, there was little agreement on the patient factors favoring reduced intensity conditioning or myeloablative conditioning." DeSalvo et al (2000) reported "wide variation… in assignment of reappointment interval with mean return intervals… ranging from 2.2 to 20.5 weeks. Sex was a significant provider independent variable… Female providers assigned earlier reappointment intervals for their patients." Solomon et al (2003) found that "established risk factors for NSAID-associated gastrointestinal toxicity were poor predictors of who was prescribed a selective COX-2 inhibitor; in contrast, physician prescribing preference was an important determinant." De Las Cuevas et al (2002) showed that "there is a remarkable degree of variation in antidepressant prescribing by psychiatrists and general practitioners; this is due to economic and social factors as much as to morbidity differences." Rochon et al (2007) found that "residents in facilities with high antipsychotic prescribing rates were about 3 times more likely than those in facilities with low prescribing rates to be dispensed an antipsychotic agent, irrespective of their clinical indication." 15 Zink et al (2001) found that "trends in the drug management of [rheumatoid arthritis] are adopted differentially by the members of the rheumatology community." Davis and Gribben (1995) found that "data from a survey of general practice in New Zealand confirm the existence of extensive variability in prescribing. Controlling for patient, diagnostic, and practitioner variables…does not reduce the extent of interpractitioner variability in prescribing rates." Moreover, de Jong et al (2009) found that decision support systems do not reduce variation in prescribing. Lichtenberg (2012) found that drug vintage is not significantly related to several important individual attributes, including insurance coverage, race, and family income as a percent of the poverty line, and that only 1/8 of the variation in drug vintage is explained by the presence or absence of more than 100 medical conditions and key demographic and socioeconomic variables.
Pharmaceutical innovation is not the only type of medical innovation that is likely to increase longevity. Other medical innovation, such as innovation in diagnostic imaging, surgical procedures, and medical devices, is also likely to increase longevity. Therefore, it would be ideal to include measures of the vintage of non-pharmaceutical medical goods (e.g. devices) and procedures in eq. (1). 16 Unfortunately, CSS does not have data on the medical procedures performed on their patients. But failure to control for nonpharmaceutical medical innovation is unlikely to bias estimates of the effect of pharmaceutical innovation on premature mortality, for several reasons.
First, the number of people exposed to pharmaceutical innovation tends to be much larger than the number of people exposed to other types of medical innovation: for example, in 2007, 62% of Americans consumed prescription drugs, while only 8% of Americans were admitted to hospitals.
17 Second, pharmaceuticals are more research-intensive than other 15 Using clinical and administrative data obtained from all facilities in a Department of Veterans Affairs integrated service network, Krein et al (2002) showed that there was variation in diabetes practice patterns at the primary care provider, provider group, and facility levels, and that the greatest amount of variance tended to be attributable to the facility level. Since the fraction of the population that is hospitalized is fairly low, the implied contribution of hospital procedure innovation to aggregate longevity growth is fairly modest-much smaller than estimates of the contribution of pharmaceutical innovation to aggregate longevity growth.
types of medical care: in 2007, prescription drugs accounted for 10% of U.S. health expenditure (Center for Medicare and Medicaid Services (2013: Table 2) ), but more than half of U.S. funding for biomedical research came from pharmaceutical and biotechnology firms (Dorsey et al (2010) ). Much of the rest came from the federal government (i.e. the NIH), and new drugs often build on upstream government research (Sampat and Lichtenberg (2011) ). Third, previous research based on U.S. data indicates that non-pharmaceutical medical innovation is not positively correlated across diseases with pharmaceutical innovation. In Appendix 2 of Lichtenberg (2013b) , it is shown that, in the U.S. during the period 1997-2007, the rate of pharmaceutical innovation was not positively correlated across diseases with the rate of medical procedure innovation and may have been negatively correlated with the rate of diagnostic imaging innovation. Also, Lichtenberg (2013c) found that estimates of the effect of pharmaceutical innovation on U.S. cancer mortality rates were insensitive to the inclusion or exclusion of measures of non-pharmaceutical medical innovation. This suggests that failure to control for other medical innovation is unlikely to result in overestimation of the effect of pharmaceutical innovation on longevity growth.
Descriptive statistics
CSS provided data on 38,842 individuals age 65 and over in 2003. About 9% (3483) of these individuals disenrolled from CSS prior to 12/31/2011; since their date of death is unknown, they were excluded from the sample. Data on the age distribution of the sample are shown in Table 2 . Almost two thirds of the sample is female. The mean age of the women (76.63) is 1.43 years higher than that of the mean (75.20). We estimated the time till death model (eq. (1)) for both sexes combined and separately by sex using the right-censored time_till_death observations, and no explanatory variables (only an intercept). This provided estimates of the Weibull shape and scale parameters (k and λ) and of mean survival time (λ (1+(1/k)). Figure 4 depicts the relationship between the age of the patient and the mean vintage of the cardiovascular drugs he or she used. Older patients tend to use older drugs: the drugs used by patients age 90 and over were about 10 years older than the drugs used by 65 year old patients. Drugs used by women were about 1.4 years older than the drugs used by men. 21 they were less likely to be hospitalized, they had fewer doctor visits, and they had fewer prescriptions for both cardiovascular drugs and drugs in general. Drug vintage is more strongly inversely related to the number of prescriptions than it is to the number of doctor visits or to whether the patient was hospitalized. As noted earlier, the inverse relationship between the vintage and quantity of drugs may be partially attributable to a "quality-quantity tradeoff": patients using newer drugs may require fewer drugs.
In some of the versions of eq. (1) we will estimate, Z will include both the total number of physician visits and the percentage distribution of those visits by specialty. Table  8 
Empirical results
Weighted least-squares estimates of key parameters of four versions of eq. (1) are presented in Table 9 . 22 All four models include cardio_drug_vintage, cardio_class_vintage, and sex and single-year-of-age dummies. Model 1 does not include any other variables. The estimates of  and  are both positive and highly significant (p-value < .0001). This indicates that, controlling for sex and age, people who used newer classes of cardiovascular drugs, and newer drugs within classes, had longer time till death than people who used older classes of cardiovascular drugs, and older drugs within classes.
Model 2 also includes a dummy variable indicating whether the person had been hospitalized in 2003; the log of the number of doctor visits in 2003; and the percentage distribution of those doctor visits by specialty. 23 As expected, the coefficients on the hospitalization dummy and the log of the number of doctor visits are negative and highly significant: people who were hospitalized and who visited the doctor most frequently in 2003 had lower life expectancy as of the end of 2003. But controlling for these variables has virtually no effect on the cardio_class_vintage coefficient and reduces the cardio_drug_vintage coefficient by less than 20%. 22 Estimates of all parameters of the most inclusive estimated version (model 4) are presented in Appendix Table 1 . 23 The physician specialty classification is shown in Table 8 . Model 3 also includes the log of the number of prescriptions in 2003. The coefficient on this variable is negative and highly significant: people who consumed more prescriptions in 2003 had lower life expectancy as of the end of 2003, ceteris paribus. Controlling for this variable has virtually no effect on the cardio_drug_vintage coefficient, but it reduces the magnitude of the cardio_class_vintage coefficient by 70%. ( and  are still highly significant (p-value < .0001)). Since using newer drugs may reduce the number of prescriptions a person has-the "quality-quantity tradeoff"-estimates of  and  from model 3 may be underestimates of the true effect of cardiovascular drug innovation on longevity.
Model 4 also includes the percentage distribution of 2003 prescriptions by main anatomical group. 24 Controlling for these variables has very little effect on the estimates of the other parameters. Now we will use the estimates of  and from models 2 and 4 to calculate the contribution of cardiovascular drug innovation to the increase in longevity of elderly residents of [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] , and that it increased their longevity by almost 6 months (= 46% × 1.0 years). Estimates of model 4 (which controlled for the number of prescriptions and their distribution by main anatomical group, as well as for the number of doctor visits and their distribution by specialty, whether the person was hospitalized, sex, and age) imply that cardiovascular drug innovation accounted for almost a quarter of the increase in longevity among elderly residents of Switzerland during [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] , and that it increased their longevity by almost 3 months. Even the more conservative estimate derived from model 2 indicates that the use of new cardiovascular drugs by elderly residents of Switzerland has been highly cost effective. Mean annual expenditure on cardiovascular drugs among elderly CSS enrollees with a heart condition was 194 USD in 2011. 25 For a 76-year-old, expected (undiscounted) future 24 The WHO ATC anatomical main group classification in shown in Table 6 . 25 This figure is reasonably similar to an estimate derived from other data sources. According to the OECD, in 2011 in Switzerland, per capita expenditure on pharmaceuticals was $531 (US$ purchasing power parity Aldy and Viscusi (2008) estimated that, in the U.S., the average value of (willingness to pay for) a life-year is $300,000.
Summary and conclusions
Previous investigators have argued that one of the two most important contributors to improved human survival is the treatment of cardiovascular disease. Among Swiss inhabitants age 65 and over, 90% of the 1994-2010 decline in the overall death rate was due to the decline in the rate of deaths from diseases of the circulatory system. Little if any of the decline in cardiovascular mortality is likely to have been due to changes in behavioral risk factors, especially tobacco use and obesity. This study has examined the impact of cardiovascular drug innovation on the longevity of elderly residents of Switzerland using cross-sectional patient-level data on about 22 thousand patients insured by a major health insurer (CSS) during the period 2003-2011. We investigated the effect of the vintage (world launch year) of the cardiovascular drugs used by an individual in 2003 on his or her longevity (time till death), controlling for several demographic characteristics and indicators of health status. We were able to track a patient's vital status until 12/31/2011: 8 years after the end of the period in which cardiovascular drug use (and other variables) were measured.
Our estimates indicated that people who used newer cardiovascular drugs in 2003 had longer time till death than people who used older cardiovascular drugs, controlling for the number of 2003 prescriptions and their distribution by main anatomical group, the number of 2003 doctor visits and their distribution by specialty, whether the person was hospitalized in 2003, sex, and age. Our most conservative estimates implied that cardiovascular drug innovation accounted for almost a quarter of the increase in longevity among elderly residents of Switzerland during [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] , and that it increased their longevity by almost 3 months. Other estimates were about twice as large. All of the estimates were consistent with the hypothesis that newer classes of drugs tend to be therapeutically superior to older classes of drugs, and that newer drugs tend to be superior to older drugs within the same class.
Even our more conservative estimate indicated that the use of new cardiovascular drugs by elderly residents of Switzerland has been highly cost effective. Our conservative estimate of the cost per life-year gained from cardiovascular drug innovation was below $10,000, and some economists have argued that the value of a statistical life-year is as high as $300,000. 
